Latest news with #JohnnyYu
Yahoo
3 days ago
- Business
- Yahoo
M-novator Demo Day Ignites Medical Innovation, Shaping the Future of MedTech
TAIPEI, June 6, 2025 /PRNewswire/ -- On the opening day of Medical Taiwan 2025, Mosaic Venture Lab, as a partner of the M-novator, is dedicated to acting as a bridge connecting Taiwan's and international innovative energy. Through its investment and ecosystem collaboration platform, it accelerates the growth of global high-quality startups in Taiwan, fosters cross-border collaborations, and brings more international funding and business opportunities to Taiwan's smart healthcare industry. The M-novator startup teams hail from Taiwan, the United States, South Korea, Belgium, and Israel. Examples include US-based InFocus Therapeutics, which focuses on developing RNA-targeted drugs, and Taiwan's own Pulxion, which has made breakthroughs in AI carotid artery detection, showcasing the international vitality of medical innovation. These pioneering startups, whose technologies represent cutting-edge advancements in the medical field, showcased in their Demo Day pitches precision artificial intelligence for diagnostics and data analysis, intuitive digital health platforms, seamless integration of medical devices (such as advanced endoscopes and smart wearables), and data-driven clinical decision support tools. A key theme of Medical Taiwan 2025 is the significant contribution of ecosystem builders in nurturing early-stage startups to achieve global impact. Johnny Yu, Founder and Chairman of CellTech Innovation Venture Studio and Managing Director of Mosaic Venture Lab, delivered a keynote speech on global MedTech trends and pressures, covering population aging, complex regulatory frameworks, and lengthy development cycles. Johnny highlighted key obstacles faced by early-stage startups: the lab-to-market translation gap, complex regulatory hurdles, funding constraints, and the complexities of market entry. He emphasized that ecosystem builders such as accelerators, venture studios, academic incubators, and government innovation departments play a crucial role in overcoming these challenges. Ryan Jin, Manager at Singapore's Centre for Healthcare Innovation, emphasized in his speech that while innovation is crucial, its effective integration into existing healthcare systems requires strategic partnerships. He acknowledged the common difficulties in collaboration between startups and healthcare institutions, citing systemic misalignments, "last-mile" barriers, and a lack of bridging infrastructure. To overcome these issues, Ryan stressed the need for streamlined processes, strong support for innovation adoption, and the establishment of clear communication channels. A highlight of the Demo Day, the panel discussion "Navigating Taiwan's MedTech Ecosystem" featured panelists including Jowy Tani, CEO of Taipei Medical University BioMed Accelerator; Nina Feng, Managing Director of Vivo Capital Taiwan; and Yenchen Huang, Vice President of Diamond Biofund. The panel aims to provide actionable insights for international MedTech and AI startups seeking to enter and thrive in the Taiwanese and Asian markets, focusing on strategies for clinical adoption, supply chain collaboration, and market entry. Mosaic Venture Lab is a venture capital accelerator focused on digital health, smart mobility, and semiconductor innovation. It collaborates with global automotive OEMs and Tier-1 suppliers to drive technological innovation and optimize business models, and is dedicated to discovering and nurturing innovative technologies from Taiwan, Japan, and South Korea to connect with major European and American companies. Media Contact:Jade ChengSr. Project ManagerMosaic Venture Lab - Partner of Medical Taiwan 2025 M-novatorEmail: jc@ Website: View original content to download multimedia: SOURCE Mosaic Venture Lab Co.,Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
M-novator Demo Day Ignites Medical Innovation, Shaping the Future of MedTech
TAIPEI, June 6, 2025 /PRNewswire/ -- On the opening day of Medical Taiwan 2025, Mosaic Venture Lab, as a partner of the M-novator, is dedicated to acting as a bridge connecting Taiwan's and international innovative energy. Through its investment and ecosystem collaboration platform, it accelerates the growth of global high-quality startups in Taiwan, fosters cross-border collaborations, and brings more international funding and business opportunities to Taiwan's smart healthcare industry. The M-novator startup teams hail from Taiwan, the United States, South Korea, Belgium, and Israel. Examples include US-based InFocus Therapeutics, which focuses on developing RNA-targeted drugs, and Taiwan's own Pulxion, which has made breakthroughs in AI carotid artery detection, showcasing the international vitality of medical innovation. These pioneering startups, whose technologies represent cutting-edge advancements in the medical field, showcased in their Demo Day pitches precision artificial intelligence for diagnostics and data analysis, intuitive digital health platforms, seamless integration of medical devices (such as advanced endoscopes and smart wearables), and data-driven clinical decision support tools. A key theme of Medical Taiwan 2025 is the significant contribution of ecosystem builders in nurturing early-stage startups to achieve global impact. Johnny Yu, Founder and Chairman of CellTech Innovation Venture Studio and Managing Director of Mosaic Venture Lab, delivered a keynote speech on global MedTech trends and pressures, covering population aging, complex regulatory frameworks, and lengthy development cycles. Johnny highlighted key obstacles faced by early-stage startups: the lab-to-market translation gap, complex regulatory hurdles, funding constraints, and the complexities of market entry. He emphasized that ecosystem builders such as accelerators, venture studios, academic incubators, and government innovation departments play a crucial role in overcoming these challenges. Ryan Jin, Manager at Singapore's Centre for Healthcare Innovation, emphasized in his speech that while innovation is crucial, its effective integration into existing healthcare systems requires strategic partnerships. He acknowledged the common difficulties in collaboration between startups and healthcare institutions, citing systemic misalignments, "last-mile" barriers, and a lack of bridging infrastructure. To overcome these issues, Ryan stressed the need for streamlined processes, strong support for innovation adoption, and the establishment of clear communication channels. A highlight of the Demo Day, the panel discussion "Navigating Taiwan's MedTech Ecosystem" featured panelists including Jowy Tani, CEO of Taipei Medical University BioMed Accelerator; Nina Feng, Managing Director of Vivo Capital Taiwan; and Yenchen Huang, Vice President of Diamond Biofund. The panel aims to provide actionable insights for international MedTech and AI startups seeking to enter and thrive in the Taiwanese and Asian markets, focusing on strategies for clinical adoption, supply chain collaboration, and market entry. Mosaic Venture Lab is a venture capital accelerator focused on digital health, smart mobility, and semiconductor innovation. It collaborates with global automotive OEMs and Tier-1 suppliers to drive technological innovation and optimize business models, and is dedicated to discovering and nurturing innovative technologies from Taiwan, Japan, and South Korea to connect with major European and American companies. Media Contact:Jade ChengSr. Project ManagerMosaic Venture Lab - Partner of Medical Taiwan 2025 M-novatorEmail: jc@ Website: View original content to download multimedia: SOURCE Mosaic Venture Lab Co.,Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Automotive
- Yahoo
FSP Group and Mosaic Venture Lab Launch Incubation Fund to Propel Taiwanese Startups onto the Global Stage
TAIPEI, June 5, 2025 /PRNewswire/ -- FSP Group (FSP TECHNOLOGY INC, TSE: 3015), a leading global power supply brand, and Mosaic Venture Lab, a venture accelerator specializing in digital health, smart mobility, and semiconductor innovation, today announced their official collaboration to establish an incubation fund. This fund aims to foster Taiwanese startups, with a focus on specialized applications within the semiconductor, mobility, and artificial intelligence industries. The FSP-MVL Innovation & Sustainability Fund will provide capital, technical and manufacturing resources, and international market connections to help Taiwanese startup teams accelerate their growth from the seed stage and expand into global markets. Startups at the seed stage often face the "valley of death." While Taiwanese startup teams generally possess impressive technical capabilities and R&D strength, they often lack accelerator guidance for their business models, leading to difficulties in fundraising and business development. This is precisely why FSP Group hopes to leverage Mosaic Venture Lab's expertise to help these early-stage startups develop scalable business models. Since its establishment in 1993, FSP Group has been committed to providing comprehensive green energy solutions, with products used in ICT, consumer electronics, industrial, lighting, medical, and new energy technologies. Beyond its leading position in R&D, FSP Group also invests significant resources in employee welfare, social engagement, and environmental sustainability, striving to drive progress through innovation, implement green manufacturing, and fulfill its corporate social responsibility. Mosaic Venture Lab focuses on discovering and nurturing innovative technologies in Taiwan, Japan, and Korea. It collaborates with renowned global automotive manufacturers such as the VW Group and AUDI, as well as Tier-1 supplier Continental Group. In digital health, Mosaic Venture Lab partners with Medtronic to promote digital health, smart mobility, and semiconductor innovation. The newly established incubation fund will concentrate on three specialized industry applications: Semiconductors: Supporting technological innovation in advanced packaging, sensors, and AI chips. Mobility: Driving innovative applications in electric vehicles, smart vehicle connectivity, and autonomous driving. Artificial Intelligence: Enhancing AI applications in manufacturing, healthcare, and finance to improve efficiency and innovation. "Mosaic Venture Lab is one of the few accelerators in Taiwan with a proven track record of overseas business expansion," said Paul Yao, Spokesperson for FSP Group. "Through this partnership, we aim to combine FSP's expertise in power technology and green energy with Mosaic Venture Lab's experience in startup acceleration and international connections to build a supportive ecosystem for Taiwanese startups." Johnny Yu, Managing Director at Mosaic Venture Lab, stated, "Taiwan possesses a solid foundation in semiconductors, smart mobility, and digital health. We look forward to using this fund to discover and cultivate more internationally competitive startup teams, driving Taiwanese innovation globally." The fund is expected to officially launch in the third quarter of 2025 and will collaborate with various universities, research institutions, and industry partners in Taiwan to establish a comprehensive startup support platform. About FSP Group FSP Group is a leading professional manufacturer of power supplies globally. Since its establishment in 1993, guided by its philosophy of "Service, Professionalism, and Innovation," FSP Group has continuously positioned itself as a comprehensive green energy solutions provider. By leveraging its leading position in power technology, it deepens its commitment to the green energy sector, offering competitive and high-quality products. FSP Group aims to be the most reliable partner for customers, consumers, and suppliers, jointly creating optimal value. FSP Group continues to advance its R&D, focusing on ultra-high efficiency, extended lifespan, and new energy. It applies its accumulated power technology expertise to a wider range of applications, including forward-looking products in ICT, consumer electronics, industrial, lighting, medical, and new energy technologies. Adhering to its vision of sustainable operation, FSP Group establishes an international brand image for green products, conveys its 3S (Safe, Stable, Saving) philosophy, and fulfills its corporate social responsibility. For more information, visit About Mosaic Venture Lab Mosaic Venture Lab is a venture accelerator focused on digital health, smart mobility, and semiconductor innovation. It collaborates with global automotive OEMs and Tier-1 suppliers to drive technological innovation and optimize business models. Mosaic Venture Lab is dedicated to discovering and nurturing innovative technologies in Taiwan, Japan, and Korea to connect them with leading European and American enterprises. For more information, visit For further information, please contact: FSP Group Spokesperson: cqe@ Venture Lab Media Contact: jy@ View original content to download multimedia: SOURCE Mosaic Venture Lab Co.,Ltd. Sign in to access your portfolio
Yahoo
4 days ago
- Automotive
- Yahoo
FSP Group and Mosaic Venture Lab Launch Incubation Fund to Propel Taiwanese Startups onto the Global Stage
TAIPEI, June 5, 2025 /PRNewswire/ -- FSP Group (FSP TECHNOLOGY INC, TSE: 3015), a leading global power supply brand, and Mosaic Venture Lab, a venture accelerator specializing in digital health, smart mobility, and semiconductor innovation, today announced their official collaboration to establish an incubation fund. This fund aims to foster Taiwanese startups, with a focus on specialized applications within the semiconductor, mobility, and artificial intelligence industries. The FSP-MVL Innovation & Sustainability Fund will provide capital, technical and manufacturing resources, and international market connections to help Taiwanese startup teams accelerate their growth from the seed stage and expand into global markets. Startups at the seed stage often face the "valley of death." While Taiwanese startup teams generally possess impressive technical capabilities and R&D strength, they often lack accelerator guidance for their business models, leading to difficulties in fundraising and business development. This is precisely why FSP Group hopes to leverage Mosaic Venture Lab's expertise to help these early-stage startups develop scalable business models. Since its establishment in 1993, FSP Group has been committed to providing comprehensive green energy solutions, with products used in ICT, consumer electronics, industrial, lighting, medical, and new energy technologies. Beyond its leading position in R&D, FSP Group also invests significant resources in employee welfare, social engagement, and environmental sustainability, striving to drive progress through innovation, implement green manufacturing, and fulfill its corporate social responsibility. Mosaic Venture Lab focuses on discovering and nurturing innovative technologies in Taiwan, Japan, and Korea. It collaborates with renowned global automotive manufacturers such as the VW Group and AUDI, as well as Tier-1 supplier Continental Group. In digital health, Mosaic Venture Lab partners with Medtronic to promote digital health, smart mobility, and semiconductor innovation. The newly established incubation fund will concentrate on three specialized industry applications: Semiconductors: Supporting technological innovation in advanced packaging, sensors, and AI chips. Mobility: Driving innovative applications in electric vehicles, smart vehicle connectivity, and autonomous driving. Artificial Intelligence: Enhancing AI applications in manufacturing, healthcare, and finance to improve efficiency and innovation. "Mosaic Venture Lab is one of the few accelerators in Taiwan with a proven track record of overseas business expansion," said Paul Yao, Spokesperson for FSP Group. "Through this partnership, we aim to combine FSP's expertise in power technology and green energy with Mosaic Venture Lab's experience in startup acceleration and international connections to build a supportive ecosystem for Taiwanese startups." Johnny Yu, Managing Director at Mosaic Venture Lab, stated, "Taiwan possesses a solid foundation in semiconductors, smart mobility, and digital health. We look forward to using this fund to discover and cultivate more internationally competitive startup teams, driving Taiwanese innovation globally." The fund is expected to officially launch in the third quarter of 2025 and will collaborate with various universities, research institutions, and industry partners in Taiwan to establish a comprehensive startup support platform. About FSP Group FSP Group is a leading professional manufacturer of power supplies globally. Since its establishment in 1993, guided by its philosophy of "Service, Professionalism, and Innovation," FSP Group has continuously positioned itself as a comprehensive green energy solutions provider. By leveraging its leading position in power technology, it deepens its commitment to the green energy sector, offering competitive and high-quality products. FSP Group aims to be the most reliable partner for customers, consumers, and suppliers, jointly creating optimal value. FSP Group continues to advance its R&D, focusing on ultra-high efficiency, extended lifespan, and new energy. It applies its accumulated power technology expertise to a wider range of applications, including forward-looking products in ICT, consumer electronics, industrial, lighting, medical, and new energy technologies. Adhering to its vision of sustainable operation, FSP Group establishes an international brand image for green products, conveys its 3S (Safe, Stable, Saving) philosophy, and fulfills its corporate social responsibility. For more information, visit About Mosaic Venture Lab Mosaic Venture Lab is a venture accelerator focused on digital health, smart mobility, and semiconductor innovation. It collaborates with global automotive OEMs and Tier-1 suppliers to drive technological innovation and optimize business models. Mosaic Venture Lab is dedicated to discovering and nurturing innovative technologies in Taiwan, Japan, and Korea to connect them with leading European and American enterprises. For more information, visit For further information, please contact: FSP Group Spokesperson: cqe@ Venture Lab Media Contact: jy@ View original content to download multimedia: SOURCE Mosaic Venture Lab Co.,Ltd. Sign in to access your portfolio
Forbes
25-04-2025
- Health
- Forbes
This Dataset can Ignite An AI Revolution In Cancer Research
Imagine accelerating the discovery of new therapeutics through the development of AI models for mining drug-cell interactions at unprecedented resolution. Tahoe Therapeutics (formerly Vevo) new release may have redefined the race to map the human cellular landscape in cancer. AI and data driven drug-discovery. getty In an unusual move, Tahoe Therapeutics has released 'Tahoe 100M', a massive open-source dataset encompassing 100 million single-cell data points and 60,000 experiments, mapping 1,100 drug treatments across 50 cancer types. Tahoe 100M brings a 50-fold increase in publicly available perturbational single-cell data, positioning itself in the world's largest single cell repository. Tahoe 100M includes what researchers call 'single cell transcriptomics profiles', i.e., a comprehensive list of gene expression data for each individual cell. These 'profiles' provide a snapshot of each cell and how it responds to drug perturbations, portraying a more accurate mosaic of tumor cell interactions. Thus, researchers can use the mosaic to understand the behavior of individual cells and define the impact of cancer heterogeneity on the development of effective treatments. Dr. Johnny Yu, co-founder and technology platform developer at Tahoe, describes the company's unique 'Mosaic Platform', used to generate the dataset, as 'a technology that creates a 'mosaic tumor' that allows testing drugs across multiple cancer types simultaneously and at high throughput'. The 'Mosaic Platform', combined with single-cell resolution, yields 'approximately 20,000 measurements across all protein-coding genes per assay" he continues, 'offering a unique level of cellular granularity'. Using this approach ensures the dataset's immediate practical value, making it a precious resource for AI modeling. Tahoe Therapeutics and the Arc Institute have recently partnered in the launch of the Arc Virtual Cell Atlas: the most comprehensive and diverse public database of single-cell level transcriptomic data across a wide range of perturbations. These data can be obtained for free and used for further analysis and AI modeling. Just in the last month, the dataset has been downloaded almost 11,000 times on Hugging Face, a data sharing platform. Dr. Hani Goodarzi, Tahoe's scientific co-founder, Core Investigator at the Arc Institute and UCSF Professor, puts the dataset into context: 'Tahoe's 'Mosaic Platform' helped minimize 'batch effects', which can make single cell data difficult to compare, offering a more consistent and reliable resource for modeling'. While recent technological advances in using AI, such as the AlphaFold 3 model, have fundamentally unlocked the ability to predict protein structures and drug interactions, understanding patient biology complexity remains a critical challenge. At this intersection, the potential impact of single-cell perturbation datasets on drug discovery can be profound. 'Tahoe 100M enables the building of comprehensive models that can predict drug interactions across diverse patient populations,' states Dr. Nima Alidoust, co-founder and CEO at Tahoe. To develop effective cancer treatments, we need to understand biological interactions beyond simple protein binding. Datasets such as Tahoe 100M account for patient complexity from the earliest stages of drug discovery, thus, having the potential to unlock novel 'AI-first' approaches to drug discovery. Dr. Bo Wang, chief AI scientist for the University Health Network in Canada and among the leading experts in AI for biology and healthcare, believes that the release of this dataset is 'a big deal for the field'. His lab developed the single-cell GPT model (scGPT), one of the first attempts to apply AI large language modeling to single-cell data. This model was trained using 33 million human cells from tissues such as heart, brain, blood, etc. and allows accurate cell type classification in single-cell studies. He believes that 'the Tahoe 100M dataset significantly extends our ability to train AI models to learn more nuanced, dosage-dependent cellular responses in perturbation studies across different cancer types, which help portray more generalizable AI models for drug development'. He is confident that such models will provide more accurate means for early patient stratification and for in silico screening of patient response for precise treatment selection. AI modeling of single cell networks. getty The generous release of Tahoe 100M is a potential turning point for deciphering cancer vulnerabilities at scale and can trigger an open-source data sharing momentum in cancer research. By providing unprecedented access to high-quality, large-scale single-cell data, Tahoe is promoting a more open, collaborative approach to scientific discovery. This is important as recent reports warn about thousands of 3D protein structures and other disease-relevant big datasets held within the vaults of private companies. The release of Tahoe 100M may represent a first step towards creating the 'internet of biology', laying the foundation for the development of truly transformative AI models to integrate and understand cellular biology and drug development at high speed.
